Qiongwei Tang, Sisi Zhu, Nannan Hu, Sainan Yin, Yuhong Yang, Yigang Teng, Dongliang Song, Xiang Liu
{"title":"经改造的 T7 RNA 聚合酶通过降低末端转移酶和 RNA 依赖性 RNA 聚合酶的活性,减少了 dsRNA 的形成。","authors":"Qiongwei Tang, Sisi Zhu, Nannan Hu, Sainan Yin, Yuhong Yang, Yigang Teng, Dongliang Song, Xiang Liu","doi":"10.1111/febs.70051","DOIUrl":null,"url":null,"abstract":"<p><p>T7 RNA polymerase (RNAP), the preferred tool for in vitro transcription (IVT), can generate double-stranded RNA (dsRNA) by-products that elicit immune stress and pose safety concerns. By combining the molecular beacon-based fluorescence-activated droplet sorting (FADS) utilized for random library screening with site-directed mutagenesis aimed at facilitating conformational changes in T7 RNAP, we successfully identified four mutants that exhibit reduced dsRNA content: M1 (V214A), M7 (F162S/A247T), M11 (K180E) and M14 (A70Q). Furthermore, the combinatorial mutant M17 (A70Q/F162S/K180E) exhibited significantly reduced dsRNA production under various conditions. Cellular experiments confirm the application potential of the mutants, displaying mitigated immune stress responses and enhanced protein translation compared to the wild-type protein. We then observed a close correlation between the production of dsRNA and the terminal transferase and RNA-dependent RNAP (RDRP) activities of T7 RNAP. The terminal transferase activity adds several nucleotides to the terminus of RNAs, while the RDRP activity extends the complementary region formed by self-pairing. In summary, we developed a novel approach for engineering T7 RNAP and demonstrated its potential in screening for T7 RNAP variants with reduced dsRNA production or improved product integrity.</p>","PeriodicalId":94226,"journal":{"name":"The FEBS journal","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Engineered T7 RNA polymerase reduces dsRNA formation by lowering terminal transferase and RNA-dependent RNA polymerase activities.\",\"authors\":\"Qiongwei Tang, Sisi Zhu, Nannan Hu, Sainan Yin, Yuhong Yang, Yigang Teng, Dongliang Song, Xiang Liu\",\"doi\":\"10.1111/febs.70051\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>T7 RNA polymerase (RNAP), the preferred tool for in vitro transcription (IVT), can generate double-stranded RNA (dsRNA) by-products that elicit immune stress and pose safety concerns. By combining the molecular beacon-based fluorescence-activated droplet sorting (FADS) utilized for random library screening with site-directed mutagenesis aimed at facilitating conformational changes in T7 RNAP, we successfully identified four mutants that exhibit reduced dsRNA content: M1 (V214A), M7 (F162S/A247T), M11 (K180E) and M14 (A70Q). Furthermore, the combinatorial mutant M17 (A70Q/F162S/K180E) exhibited significantly reduced dsRNA production under various conditions. Cellular experiments confirm the application potential of the mutants, displaying mitigated immune stress responses and enhanced protein translation compared to the wild-type protein. We then observed a close correlation between the production of dsRNA and the terminal transferase and RNA-dependent RNAP (RDRP) activities of T7 RNAP. The terminal transferase activity adds several nucleotides to the terminus of RNAs, while the RDRP activity extends the complementary region formed by self-pairing. In summary, we developed a novel approach for engineering T7 RNAP and demonstrated its potential in screening for T7 RNAP variants with reduced dsRNA production or improved product integrity.</p>\",\"PeriodicalId\":94226,\"journal\":{\"name\":\"The FEBS journal\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The FEBS journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/febs.70051\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The FEBS journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/febs.70051","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Engineered T7 RNA polymerase reduces dsRNA formation by lowering terminal transferase and RNA-dependent RNA polymerase activities.
T7 RNA polymerase (RNAP), the preferred tool for in vitro transcription (IVT), can generate double-stranded RNA (dsRNA) by-products that elicit immune stress and pose safety concerns. By combining the molecular beacon-based fluorescence-activated droplet sorting (FADS) utilized for random library screening with site-directed mutagenesis aimed at facilitating conformational changes in T7 RNAP, we successfully identified four mutants that exhibit reduced dsRNA content: M1 (V214A), M7 (F162S/A247T), M11 (K180E) and M14 (A70Q). Furthermore, the combinatorial mutant M17 (A70Q/F162S/K180E) exhibited significantly reduced dsRNA production under various conditions. Cellular experiments confirm the application potential of the mutants, displaying mitigated immune stress responses and enhanced protein translation compared to the wild-type protein. We then observed a close correlation between the production of dsRNA and the terminal transferase and RNA-dependent RNAP (RDRP) activities of T7 RNAP. The terminal transferase activity adds several nucleotides to the terminus of RNAs, while the RDRP activity extends the complementary region formed by self-pairing. In summary, we developed a novel approach for engineering T7 RNAP and demonstrated its potential in screening for T7 RNAP variants with reduced dsRNA production or improved product integrity.